CCC
ABBV icon

Crescent Capital Consulting’s AbbVie ABBV Stock Holding History

Crescent Capital Consulting’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1.18M Buy
8,714
+5
+0.1% +$591 0.19% 87
2021
Q3 		$941K Hold
8,709
– – 0.17% 92
2021
Q2 		$982K Sell
8,709
-21
-0.2% -$2.37K 0.18% 82
2021
Q1 		$944K Buy
8,730
+2,876
+49% +$308K 0.21% 82
2020
Q4 		$629K Buy
+5,854
New +$563K 0.16% 90

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Crescent Capital Consulting's ABBV Position: Q4 2021 in Review

Crescent Capital Consulting increased its AbbVie (ABBV) stake by 0.06% in Q4 2021, buying an estimated $591 and bringing the position to 8,714 shares worth $1.18M. The position accounts for 0.19% of the portfolio, ranked #87.

Crescent Capital Consulting first reported a position in ABBV in Q4 2020 and has held it in 5 quarters since. 2,981 funds tracked by Wall St. Rank hold ABBV as of Q4 2021.

  • Crescent Capital Consulting held 8,714 shares of AbbVie worth $1.18M as of Q4 2021.
  • Crescent Capital Consulting bought 5 AbbVie shares in Q4 2021, an estimated $591.
  • AbbVie made up 0.19% of Crescent Capital Consulting's portfolio in Q4 2021, its #87 holding.
  • Crescent Capital Consulting first reported a position in AbbVie in Q4 2020 and has held it in 5 quarters since.
  • 2,981 funds tracked by Wall St. Rank held AbbVie as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.